Apellis Pharmaceuticals (APLS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Apellis Pharmaceuticals, Inc. (APLS) reported $458.58 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 133%. EPS of $1.67 for the same period compares to -$0.46 a year ago.The reported revenue represents a surprise of +25.22% over the Zacks Consensus Estimate of $366.21 million. With the consensus EPS estimate being $1.03, the EPS surprise was +62.14%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Apellis Pharmaceuticals performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Revenue- Product revenue, net: $177.76 million versus the nine-analyst average estimate of $178.43 million. The reported number represents a year-over-year change of +0.7%.Revenue- Licensing and other revenue: $280.82 million versus $126.67 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +1286.2% change.Product Revenue- EMPAVELI: $26.83 million compared to the $22.06 million average estimate based on seven analysts. The reported number represents a change of +9% year over year.Product Revenue- SYFOVRE: $150.93 million compared to the $156.55 million average estimate based on seven analysts. The reported number represents a change of -0.7% year over year.View all Key Company Metrics for Apellis Pharmaceuticals here>>>Shares of Apellis Pharmaceuticals have returned +30.1% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Apellis Pharmaceuticals, Inc. (APLS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks